Published in Medical Letter on the CDC and FDA, January 24th, 2010
"Individualized risk-benefit calculation regarding the use of tamoxifen is burdensome for practical clinical use. We propose a Chemoprevention Indication Score (CIS) that is easy to Compute and reliable to identify women suitable for chemoprevention. Chart-review of all patients attending a university-based high-risk breast clinic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA